MedTrace Logo

Intake of Omega 3 in Morbidly Obese Patients

NCT02113696 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2014-07-08

No results posted yet for this study

Summary

Ingestion of capsules of omega 3 EPA and DHA, with 1.8 g of EPA and 1.2 g DHA for morbidly obese patients, will improve the inflammatory status? C-reactive protein? Weight?

Conditions

  • Morbid Obesity

Interventions

DIETARY_SUPPLEMENT

Omega 3 intake, morbid obesity

Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.

DIETARY_SUPPLEMENT

Placebo Capsules

They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.

Sponsors & Collaborators

  • Pontificia Universidade Católica do Rio Grande do Sul

    lead OTHER

Principal Investigators

  • Claudio C Motin, orientador · Centro de Obesidade Mórbida da Pontificia Universidade Católica do RS

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-06-30
Completion
2014-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02113696 on ClinicalTrials.gov